22 April 2013 | News | By BioSpectrum Bureau
Spinchrom Life Sciences to market Pall's ForteBio Division's BLItz protein analysis platform
Singapore: Pall India entered into an exclusive India distribution agreement with a leading biosupplier, Spinchrom Life Sciences, a division of Spinco Biotech to market in India ForteBio's BLItz system. The revolutionary platform uniquely enables scientists to conduct label-free analyses of proteins using small sample volumes easily and cost-efficiently at their laboratory bench. ForteBio is a division of Pall Life Sciences and a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products.
Historically, institutions have used label-free assays selectively and relegated them to their core laboratories due to their high complexity and expense. This practice creates bottlenecks in biotherapeutic research and development, as scientists may wait days or weeks to schedule their experiments and then hours or longer to obtain results.
The BLItz system is small, taking up less surface area than a tablet personal computer, so it can fit easily in an individual scientist's workspace. It is simple to use and requires only four microliters of sample, which is 15-to-20 times less volume than needed for traditional, surface plasmon resonance (SPR)-based label-free assays or microplate-based ELISA assays. The BLItz system utilizes the same Bio-Layer Interferometry (BLI) technology that powers ForteBio's flagship Octet instrumentation platform, which enables real-time kinetics, affinity and quantitation measurements in high-throughput applications, with unprecedented ease of use and cost-efficiency.
The BLItz system is designed for any researcher working with proteins, particularly those who analyze column fractions, monitor protein expression, perform reagent QC, identify mechanism of action and signaling and run protein engineering studies. Additionally, the BLItz system's Dip and Read assays utilize disposable, ready-to-use biosensors that uniquely provide results in seconds to minutes.
Mr Sachin Indane, director, BioPharm, Pall India, said that, "Given the growing biosimilar and proteomic activity in India, scientists' ability to understand protein interactions is increasingly a key success factor. The BLItz technology offers great value by means of a very cost-effective, simple and fast technology platform. The BLItz platform will revolutionize the use of label-free protein analysis here by making it more accessible than ever to individual bench scientists and this will help to further advance biotherapeutic development in India."